NOTION试验五年临床与超声心动图结果:低外科风险患者TAVR与SAVR比较
NOTION试验将≥70岁孤立性重度主动脉瓣狭窄患者随机分配至自膨胀CoreValve TAVR组(n=145)或SAVR组(n=135),随访5年。两组主要复合终点(全因死亡、卒中或心肌梗死)无差异(38.0% vs 36.3%,P=0.86)。TAVR组瓣膜面积更大、平均跨瓣压差更低,但中/重度主动脉瓣反流和新起搏器植入率更高。
要点
- 5年主要复合终点TAVR与SAVR无差异(38.0% vs 36.3%,P=0.86)
- TAVR组瓣膜面积更大(1.7 vs 1.2 cm²)、跨瓣压差更低(8.2 vs 13.7 mmHg)
- TAVR组中/重度主动脉瓣反流(8.2% vs 0.0%)和新起搏器(43.7% vs 8.7%)更高
核心结论
- 在较低外科风险的重度主动脉瓣狭窄患者中,自膨胀瓣膜TAVR与SAVR术后5年主要临床结局无统计学差异。
- TAVR组术后中/重度主动脉瓣反流和新起搏器植入率显著高于SAVR组。
研究设计与样本
- NOTION试验为在3个北欧中心进行的随机对照试验,按1:1随机分配。
- 纳入≥70岁孤立性重度主动脉瓣狭窄患者,TAVR组使用自膨胀CoreValve瓣膜(n=145),SAVR组使用带支架生物瓣(n=135)。
- 主要复合终点为1年全因死亡、卒中或心肌梗死,依据VARC-2标准定义;本次报告5年临床与超声心动图结果。
主要发现
- 5年复合终点Kaplan-Meier估计TAVR组38.0%、SAVR组36.3%,log-rank检验P=0.86,各组分亦无差异。
- TAVR组人工瓣膜面积大于SAVR组(1.7 cm² vs 1.2 cm²,P<0.001),平均跨瓣压差更低(8.2 mmHg vs 13.7 mmHg,P<0.001),两者随时间不变。
- TAVR组中/重度总主动脉瓣反流发生率高于SAVR组(8.2% vs 0.0%,P<0.001)。
- TAVR组新起搏器植入率高于SAVR组(43.7% vs 8.7%,P<0.001)。
- 4例患者接受人工瓣膜再干预,功能结局无差异。
关键数值与推荐
- 基线平均年龄79.1±4.8岁,平均STS预测死亡风险评分3.0%±1.7%。
- 5年复合终点:TAVR 38.0% vs SAVR 36.3%(log-rank P=0.86)。
- 人工瓣膜面积:TAVR 1.7 cm² vs SAVR 1.2 cm²(P<0.001)。
- 平均跨瓣压差:TAVR 8.2 mmHg vs SAVR 13.7 mmHg(P<0.001)。
- 中/重度总主动脉瓣反流:TAVR 8.2% vs SAVR 0.0%(P<0.001);新起搏器:TAVR 43.7% vs SAVR 8.7%(P<0.001)。
临床怎么用
- 对于≥70岁孤立性重度主动脉瓣狭窄且外科风险较低的患者,TAVR与SAVR的5年主要临床结局相当,选择术式时可综合评估。
- TAVR后需关注主动脉瓣反流和新起搏器植入风险,SAVR后需关注较高跨瓣压差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The NOTION trial (Nordic Aortic Valve Intervention) was designed to compare transcatheter aortic valve replacement (TAVR) with surgical aortic valve replacement (SAVR) in patients ≥70 years old with isolated severe aortic valve stenosis. Clinical and echocardiographic outcomes are presented after 5 years. METHODS: Patients were enrolled at 3 Nordic centers and randomized 1:1 to TAVR using the self-expanding CoreValve prosthesis (n=145) or SAVR using any stented bioprostheses (n=135). The primary composite outcome was the rate of all-cause mortality, stroke, or myocardial infarction at 1 year defined according to Valve Academic Research Consortium-2 criteria. RESULTS: Baseline characteristics were similar. The mean age was 79.1±4.8 years and mean Society of Thoracic Surgeons Predicted Risk of Mortality score was 3.0%±1.7%. After 5 years, there were no differences between TAVR and SAVR in the composite outcome (Kaplan-Meier estimates 38.0% versus 36.3%, log-rank test P=0.86) or any of its components. TAVR patients had larger prosthetic valve area (1.7 cm2 versus 1.2 cm2, P<0.001) with a lower mean transprosthetic gradient (8.2 mm Hg versus 13.7 mm Hg, P<0.001), both unchanged over time. More TAVR patients had moderate/severe total aortic regurgitation (8.2% versus 0.0%, P<0.001) and a new pacemaker (43.7% versus 8.7%, P<0.001). Four patients had prosthetic reintervention and no difference was found for functional outcomes. CONCLUSIONS: These are currently the longest follow-up data comparing TAVR and SAVR in lower risk patients, demonstrating no statistical difference for major clinical outcomes 5 years after TAVR with a self-expanding prosthesis compared to SAVR. Higher rates of prosthetic regurgitation and pacemaker implantation were seen after TAVR. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov. Unique identifier: NCT01057173.
引用
- Thyregod HGH, Ihlemann N, Jørgensen TH, et al. Five-Year Clinical and Echocardiographic Outcomes From the NOTION Randomized Clinical Trial in Patients at Lower Surgical Risk. Circulation. 2019. PMID: 30704298. doi:10.1161/CIRCULATIONAHA.118.036606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。